Eliel Bayever

2.9k total citations
69 papers, 1.3k citations indexed

About

Eliel Bayever is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eliel Bayever has authored 69 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Molecular Biology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eliel Bayever's work include Sarcoma Diagnosis and Treatment (11 papers), Cancer-related Molecular Pathways (9 papers) and Cancer therapeutics and mechanisms (8 papers). Eliel Bayever is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Cancer-related Molecular Pathways (9 papers) and Cancer therapeutics and mechanisms (8 papers). Eliel Bayever collaborates with scholars based in United States, Germany and Spain. Eliel Bayever's co-authors include Patrick L. Iversen, Mark Arneson, Raymond W. Ruddon, Charles S. August, Anne Kessinger, Michael Bishop, Jamés O. Armitage, Gerald Zon, J. Jeffrey Malatack and Samuel J. Pirruccello and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Eliel Bayever

67 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eliel Bayever United States	20	490	350	288	184	164	69	1.3k
Victoria Stepanova Russia	23	579 1.2×	171 0.5×	339 1.2×	152 0.8×	188 1.1×	45	1.4k
Rami Kotb Canada	18	523 1.1×	475 1.4×	620 2.2×	182 1.0×	122 0.7×	85	1.4k
Andréï Tchirkov France	22	702 1.4×	389 1.1×	190 0.7×	160 0.9×	173 1.1×	88	1.7k
Daniel Kraft United States	13	596 1.2×	201 0.6×	391 1.4×	291 1.6×	60 0.4×	30	1.7k
G. Hartung Germany	17	494 1.0×	781 2.2×	307 1.1×	38 0.2×	190 1.2×	57	1.6k
Robert Emmons United States	17	617 1.3×	334 1.0×	375 1.3×	125 0.7×	44 0.3×	30	1.4k
Antonio Sorrentino Italy	21	1.7k 3.4×	361 1.0×	176 0.6×	96 0.5×	109 0.7×	36	2.4k
V. Nataf France	21	530 1.1×	298 0.9×	145 0.5×	43 0.2×	247 1.5×	61	1.5k
Jeannine T. Holden United States	17	481 1.0×	637 1.8×	239 0.8×	61 0.3×	122 0.7×	24	1.6k
Eun Ji Gang United States	17	1.1k 2.3×	291 0.8×	204 0.7×	87 0.5×	107 0.7×	27	2.1k

Countries citing papers authored by Eliel Bayever

Since Specialization

Citations

This map shows the geographic impact of Eliel Bayever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliel Bayever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliel Bayever more than expected).

Fields of papers citing papers by Eliel Bayever

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliel Bayever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliel Bayever. The network helps show where Eliel Bayever may publish in the future.

Co-authorship network of co-authors of Eliel Bayever

This figure shows the co-authorship network connecting the top 25 collaborators of Eliel Bayever. A scholar is included among the top collaborators of Eliel Bayever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliel Bayever. Eliel Bayever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wee, Wen, Anthony W. Tolcher, Cesar A. Perez, et al.. (2024). Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3173–TPS3173. 3 indexed citations

Orr, Daniel L., Cesar A. Perez, Yonina R. Murciano‐Goroff, et al.. (2023). 692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors. Annals of Oncology. 34. S482–S483. 3 indexed citations

Brewer, Molly, Roberto Angioli, Domenica Lorusso, et al.. (2020). Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecologic Oncology. 156(3). 523–529. 36 indexed citations

Richter, Joshua, Ola Landgren, John Kauh, et al.. (2018). Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 36(15_suppl). TPS3132–TPS3132. 19 indexed citations

Ramanathan, Ramesh K., Ronald L. Korn, Natarajan Raghunand, et al.. (2017). Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study. Clinical Cancer Research. 23(14). 3638–3648. 134 indexed citations

Chuk, Meredith K., Alberta Aikin, Brigitte C. Widemann, et al.. (2012). A phase I trial and pharmacokinetic study of a 24‐hour infusion of trabectedin (Yondelis®, ET‐743) in children and adolescents with relapsed or refractory solid tumors. Pediatric Blood & Cancer. 59(5). 865–869. 22 indexed citations

McMeekin, D. Scott, Alla Lisyanskaya, Marta A. Crispens, et al.. (2009). Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study. Gynecologic Oncology. 114(2). 288–292. 16 indexed citations

Mehren, Margaret von, Russell J. Schilder, J. Cheng, et al.. (2008). A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Annals of Oncology. 19(10). 1802–1809. 41 indexed citations

Malatack, J. Jeffrey, et al.. (2003). The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatric Neurology. 29(5). 391–403. 61 indexed citations

10.

Iversen, Patrick L., et al.. (2003). Continuous Infusion of Antisense Phosphorothioate Therapeutics. Humana Press eBooks. 1. 201–212.

11.

Selby, Dena M., Jonas R. Rudzki, Eliel Bayever, & Roma Chandra. (1999). Vasculopathy of small muscular arteries in pediatric patients after bone marrow transplantation. Human Pathology. 30(7). 734–740. 21 indexed citations

12.

Bishop, Michael, Jonathan Jackson, Stefano Tarantolo, et al.. (1997). Ex Vivo Treatment of Bone Marrow with Phosphorothioate Oligonucleotide OL(l)p53 for Autologous Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Journal of Hematotherapy. 6(5). 441–446. 20 indexed citations

13.

Bishop, Michael, Patrick L. Iversen, Eliel Bayever, et al.. (1996). Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.. Journal of Clinical Oncology. 14(4). 1320–1326. 119 indexed citations

14.

Krivit, William, Martin R. Klemperer, M J Cowan, et al.. (1995). Survival in Hurler's disease following bone marrow transplantation in 84 patients. Bone Marrow Transplantation. 15(1). 14 indexed citations

15.

Kamani, Naynesh, Eliel Bayever, Charles S. August, et al.. (1995). Fractionated total‐body irradiation preceding high‐dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Medical and Pediatric Oncology. 25(3). 179–184. 5 indexed citations

16.

Bayever, Eliel, Kathleen M. Haines, Patrick L. Iversen, et al.. (1994). Selective Cytotoxicity to Human Leukemic Myeloblasts Produced by Oligodeoxyribonucleotide Phosphorothioates Complementary to p53 Nucleotide Sequences. Leukemia & lymphoma. 12(3-4). 223–231. 40 indexed citations

17.

Bayever, Eliel & Patrick L. Iversen. (1994). Oligonucleotides in the treatment of leukemia. Hematological Oncology. 12(1). 9–14. 18 indexed citations

18.

Finlay, Jonathan L., Charles S. August, Roger J. Packer, et al.. (1990). High-dose multi-agent chemotherapy followed by bone marrow ‘rescue’ for malignant astrocytomas of childhood and adolescence. Journal of Neuro-Oncology. 9(3). 239–248. 59 indexed citations

19.

Bayever, Eliel, et al.. (1988). Protection of uninfected human bone marrow cells in long-term culture from G418 toxicity after retroviral-mediated transfer of the NEOr gene. Experimental Cell Research. 179(1). 168–180. 9 indexed citations

20.

Bayever, Eliel, Richard E. Champlin, Winston G. Ho, et al.. (1984). Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. The Journal of Pediatrics. 105(6). 920–925. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact